The Functional Cancer Genomics group directed by Prof. J.P. Theurillat at the Institute of Oncology Research in Bellinzona, Switzerland (http://www.ior.iosi.ch) is seeking a part-time (40-60%) technician in cancer research.
The successful candidate will work as part of an international team that is dedicated to understanding how new driver alterations culled from cancer genome characterization studies promote tumorigenesis, and how gathered insights can be exploited to develop precision medicines. The position offers excellent scientific opportunities in a highly stimulating and interdisciplinary environment involving close interactions between medical and basic scientists. Investigations range from projects related to:
- The use of innovative cell culture techniques to study the biology of prostate cancer
- Determining anti-tumor activity of novel drug-like compounds
- MSc or PhD in biology
- Working experience in basic cell culture, viral transduction, DNA cloning, and protein biochemistry techniques
- Working experience with animal models (genetically-engineered mice and tumor xenograft models) is desirable
The position is located at the Institute of Oncology Research, a leading institution in basic and translational cancer research in Southern Switzerland with state-of-the-art core facilities and competitive salaries.
For inquiry regarding this job and submission of complete applications please contact Prof. Jean-Philippe Theurillat via email: email@example.com.
Starting date: Fall or winter 2017
Selected recent publications:
– Janouskova H, et al. Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors. Accepted for publication Nat Med 2017.
– Groner A, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 2016 PMID: 27238081
– Theurillat JP, et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 2014 PMID: 25278611
– Whittaker SR, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013 PMID: 23288408
– Barbieri CE1, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012 PMID: 22610119
– Theurillat JP, et al. URI is an oncogene amplified in ovarian cancer cells and is required for their
survival. Cancer Cell 2011 PMID: 21397856